SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Clinical Aspects of Pediatric Treatment- Tim Cressey, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Current Challenges in Pediatric Drug Development- Robert Ward, MD, FAAP, FCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_6: Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir- Catia Marzolini, PharmD, PhDView Slideset
JMJosé MoltóMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_3: Pharmacokinetics of darunavir/cobicistat and etravirine alone and coadministered in HIV-infected patients- José Moltó, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_5: Confirmation of the drug-drug interaction (DDI) potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives- Dr Sophia MajeedView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_4: Evaluation of the Drug-Drug Interaction Potential between Cobicistat-Boosted Protease Inhibitors and Statins - Dr Joseph CustodioView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_2: Effects of cobicistat on tenofovir durability: is it time to rethink at TAF trials?- Dario Cattaneo, PharmD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017O_1: Single- and multiple-ascending doses (SAD/MAD) and food effect of orally administered JNJ-64155806 in healthy volunteers- Thomas Kakuda, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017Current and Future Treatment of CMV- Robin Avery, MDView Slideset
SlidesetHIVBrazilian HIV Clinical Forum 2017Clinical Case on Integrase Inhibitors Use in TB-Infected Patients- Dr. L. GrinsztejnView Slideset
SlidesetHIVBrazilian HIV Clinical Forum 2017HIV Integrase Inhibitors in an Aging Population (Polypharmacy - Comorbidities)- Dr. M.C.Rachid de LacerdaView Slideset
RERichard ElionMDSlidesetHIVBrazilian HIV Clinical Forum 2017The Role of HIV Integrase Inhibitors in PrEP & PEP- Richard ElionView Slideset
